Matt Meyerson headshot

Matt Meyerson, M.D., Ph.D.

Professor of Genetics, Harvard Medical School
Professor of Pathology, Medical Oncology, Dana-Farber Cancer Institute
Director, Center for Cancer Genome Discovery, Dana-Farber Cancer Institute
Dana Farber Cancer Institute
Author Correction: Genomic basis for RNA alterations in cancer.
Authors: Authors: Calabrese C, Davidson NR, Demircioglu D, Fonseca NA, He Y, Kahles A, Lehmann KV, Liu F, Shiraishi Y, Soulette CM, Urban L, Greger L, Li S, Liu D, Perry MD, Xiang Q, Zhang F, Zhang J, Bailey P, Erkek S, Hoadley KA, Hou Y, Huska MR, Kilpinen H, Korbel JO, Marin MG, Markowski J, Nandi T, Pan-Hammarström Q, Pedamallu CS, Siebert R, Stark SG, Su H, Tan P, Waszak SM, Yung C, Zhu S, Awadalla P, Creighton CJ, Meyerson M, Ouellette BFF, Wu K, Yang H, Brazma A, Brooks AN, Göke J, Rätsch G, Schwarz RF, Stegle O, Zhang Z.
Nature
View full abstract on Pubmed
Telomerase inhibition is an effective therapeutic strategy in TERT promoter mutant-glioblastoma models with low tumor volume.
Authors: Authors: Aquilanti E, Kageler L, Watson J, Baird DM, Jones RE, Hodges M, Szegletes ZM, Doench JG, Strathdee CA, McFaline Figueroa JR, Ligon K, Beck M, Wen PY, Meyerson M.
Neuro Oncol
View full abstract on Pubmed
Correction to "Discovery and Structure-Based Design of Potent Covalent PPAR? Inverse-Agonists BAY-4931 and BAY-0069".
Authors: Authors: Orsi DL, Pook E, Bräuer N, Friberg A, Lienau P, Lemke CT, Stellfeld T, Brüggemeier U, Pütter V, Meyer H, Baco M, Tang S, Cherniack AD, Westlake L, Bender SA, Kocak M, Strathdee CA, Meyerson M, Eis K, Goldstein JT.
J Med Chem
View full abstract on Pubmed
Discovery and characterization of orally bioavailable 4-chloro-6-fluoroisophthalamides as covalent PPARG inverse-agonists.
Authors: Authors: Orsi DL, Ferrara SJ, Siegel S, Friberg A, Bouché L, Pook E, Lienau P, Bluck JP, Lemke CT, Akcay G, Stellfeld T, Meyer H, Pütter V, Holton SJ, Korr D, Jerchel-Furau I, Pantelidou C, Strathdee CA, Meyerson M, Eis K, Goldstein JT.
Bioorg Med Chem
View full abstract on Pubmed
Correction to: Oncogenic RIT1 mutations in lung adenocarcinoma.
Authors: Authors: Berger AH, Imielinski M, Duke F, Wala J, Kaplan N, Shi G-, Andres DA, Meyerson M.
Oncogene
View full abstract on Pubmed
Functional genomic analysis of CDK4 and CDK6 gene dependency across human cancer cell lines.
Authors: Authors: Zhang Z, Golomb L, Meyerson M.
Cancer Res
View full abstract on Pubmed
Long-read sequencing reveals complex patterns of wraparound transcription in polyomaviruses.
Authors: Authors: Nomburg J, Zou W, Frost TC, Datta C, Vasudevan S, Starrett GJ, Imperiale MJ, Meyerson M, DeCaprio JA.
PLoS Pathog
View full abstract on Pubmed
Author Correction: Identification of ADAR1 adenosine deaminase dependency in a subset of cancer cells.
Authors: Authors: Gannon HS, Zou T, Kiessling MK, Gao GF, Cai D, Choi PS, Ivan AP, Buchumenski I, Berger AC, Goldstein JT, Cherniack AD, Vazquez F, Tsherniak A, Levanon EY, Hahn WC, Meyerson M.
Nat Commun
View full abstract on Pubmed
Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanoma.
Authors: Authors: Freeman SS, Sade-Feldman M, Kim J, Stewart C, Gonye ALK, Ravi A, Arniella MB, Gushterova I, LaSalle TJ, Blaum EM, Yizhak K, Frederick DT, Sharova T, Leshchiner I, Elagina L, Spiro OG, Livitz D, Rosebrock D, Aguet F, Carrot-Zhang J, Ha G, Lin Z, Chen JH, Barzily-Rokni M, Hammond MR, Vitzthum von Eckstaedt HC, Blackmon SM, Jiao YJ, Gabriel S, Lawrence DP, Duncan LM, Stemmer-Rachamimov AO, Wargo JA, Flaherty KT, Sullivan RJ, Boland GM, Meyerson M, Getz G, Hacohen N.
Cell Rep Med
View full abstract on Pubmed
Telomerase as a therapeutic target in glioblastoma.
Authors: Authors: Aquilanti E, Kageler L, Wen PY, Meyerson M.
Neuro Oncol
View full abstract on Pubmed